Using Fasudil Hydrochloride to treat gene-specific ovarian cancer
Official title: A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Run by Zhejiang Provincial People's Hospital · NCT06890858 · Data updated 2026-11-12
This study is testing if Fasudil Hydrochloride can help ovarian cancer patients with a specific genetic type feel better and improve their treatment results when added to their current chemotherapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 20 (estimated) |
| Sponsor | Zhejiang Provincial People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | April 2025 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | March 24, 2025 |
| Trial ID | NCT06890858 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are ovarian cancer patients with the A/A genotype who have experienced disease stability or progression after platinum-based chemotherapy.
✕Probably not a fit
Patients with hypotension, bleeding disorders, or abnormal liver function may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study investigates the effectiveness of Fasudil Hydrochloride in treating ovarian cancer patients with the A/A genotype. It aims to evaluate whether this treatment can improve patient outcomes by targeting the Rho signaling pathway, which is implicated in cancer cell proliferation and invasion. The study will enroll 20 patients who have shown disease stability or progression after platinum-based chemotherapy and have been confirmed to have the A/A genotype through genetic testing. The goal is to enhance the prognosis for these patients by combining Fasudil with their existing chemotherapy regimen.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the prognosis for patients with gene-specific ovarian cancer.
How similar studies have gone: Preliminary studies have shown promise in using Fasudil for similar applications, but this specific approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance. 2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A/A genotype through genetic testing. Exclusion Criteria: * 1.Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function
Where it's running
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Yang Liu, M.D.
- Email: yangliuqq2003@163.com
- Phone: 13666601475
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.